Management of CNV in PXE involves the prompt use of intravitreal anti-VEGF injections and vitrectomy with tissue plasminogen activator (tPA) for controlling CNV activity and submacular hemorrhage. The gene discussed is VEGFA; the disease is autosomal recessive inherited pseudoxanthoma elasticum.